Compassionate Use of Metvix® (Methyl Aminolevulinate) Photodynamic Therapy (PDT) in Subjects With Field Actinic Keratoses, Large/Multiple Superficial Basal Cell Carcinomas (BCCs), or Bowen's Disease
Expanded access is no longer available for this treatment.
First Posted: September 26, 2007
Last Update Posted: October 28, 2009
Information provided by:
The aim of this study is to provide this investigational drug to patients who cannot be optimally treated with conventional therapies and to collect efficacy and safety data on the use of Metvix PDT in subjects with field actinic keratoses, large/multiple superficial basal cell carcinomas (BCCs) or Bowen's disease.
|Field Actinic Keratoses Basal Cell Carcinoma Bowen's Disease||Drug: Metvix (methyl aminolevulinate)|
|Study Type:||Expanded Access What is Expanded Access?|
|Official Title:||Compassionate Use of Metvix® (Methyl Aminolevulinate) PDT in Subjects With Field Actinic Keratoses, Large/Multiple Superficial BCCs, or Bowen's Disease|
Resource links provided by NLM:
Drug Information available for: Aminolevulinic acid Aminolevulinic acid hydrochloride Methyl aminolevulinateU.S. FDA Resources
Further study details as provided by Galderma:
Drug: Metvix (methyl aminolevulinate)
Metvix (methyl aminolevulinate) (MAL), Photodynamic Therapy (PDT), cream, 160 mg/g. MAL cream will be applied for 3 hours then will be removed. The target area will then be exposed to red light (using a large-field LED light source: Aktilite 128) for 7 to 10 minutes at a dosage of 37 J/cm².
Contacts and Locations
No Contacts or Locations Provided